论文部分内容阅读
目的:比较盐酸羟考酮缓释片与盐酸曲马多缓释片对中度癌痛患者初始镇痛疗效和安全性,为临床治疗癌痛患者提供参考。方法:选取中度癌痛患者60例,将其分为观察组(羟考酮组,30例)与对照组(曲马多组,30例);观察组患者给予口服盐酸羟考酮缓释片治疗,对照组患者给予口服盐酸曲马多缓释片治疗,治疗1周后比较两组患者用药的意愿、疼痛控制率、疼痛缓解时间、BPI评分值及药物不良反应等指标。结果:观察组患者在疼痛控制率、疼痛缓解时间、BPI评分值均优于对照组(P<0.05);致便秘不良反应的发生率前者为50.00%高于后者为16.67%(P<0.05)。结论:盐酸羟考酮缓释片用于治疗中度癌痛患者初始镇痛疗效和安全性优于盐酸曲马多缓释片。
Objective: To compare the efficacy and safety of oxycodone hydrochloride sustained-release tablets and tramadol hydrochloride sustained-release tablets on the initial analgesia in patients with moderate cancer pain, and to provide reference for the clinical treatment of patients with cancer pain. Methods: Sixty patients with moderate cancer pain were selected and divided into observation group (oxycodone group, 30 cases) and control group (tramadol group, 30 cases). The observation group was given oral oxycodone hydrochloride sustained release The patients in the control group were given oral tramadol hydrochloride sustained release tablets. After one week of treatment, their willingness to use drugs, pain control rate, pain relief time, BPI score and adverse drug reactions were compared. Results: The pain control rate, pain relief time and BPI score in the observation group were better than those in the control group (P <0.05). The incidence of constipation adverse reactions was 50.00% in the observation group and 16.67% in the observation group (P <0.05) ). CONCLUSION: The initial analgesic efficacy and safety of oxycodone hydrochloride sustained-release tablets for the treatment of moderate cancer pain patients are better than that of tramadol hydrochloride sustained-release tablets.